In an effort for the development of novel antimicrobial, antimalarial and antitubercular agents, series of quinoline carboxylic acid derivatives bearing substituted pyrazole moiety were synthesized from derivatives of substituted pyrazole aldehydes, substituted aniline and pyruvic acid, through a one-pot Doebner reaction. Then the Carboxylic group was converted to an acyl chloride, N-(3-(dimethylamino) propyl) carboxamide, and alcohol functional groups. All the compounds were characterized by elemental analysis, MS, 1 H NMR and 13 C NMR spectroscopy and were screened against bacterial strains. Majority of these compounds showed potent antibacterial and antifungal activities against the tested strains of bacteria and fungi. Compounds were also screened for antitubercular and antimalarial activities. Quinoline-Pyrazole clubbed derivative showed better results when compared with the reference drugs based on their MIC values. Thus, these studies suggest that quinoline derivatives bearing pyrazole moiety are interesting scaffolds for the development of novel antimicrobial, antimalarial, and antimycobacterial agents.
Introduction
Antimicrobial [1, 2] and anti-tubercular [3] drug discovery for the past half-century has evolved exponentially with the advancements in the field of medicinal chemistry coupled with a computational screening of potential drug targets [4] . However, continuously evolving multi-drug resistant strains of bacteria and fungi such as Methicillin-resistant Staphylococcus aureus (MRSA) [5] along with the systemic side effects of the potent drugs have proven to be the key setbacks in discovering a novel treatment. In order to overcome these setbacks mounting emphasis has been given on methods for synthesizing scaffold of compounds with proven efficacy [6] , thereby retaining the systemic tolerability with enhanced antimicrobial activity. The pharmacological properties of the quinoline ring are well explained by the huge number of commercially available drugs containing this heterocyclic ring system [7, 8] (Fig. 1 ). These molecules have been examined for decades and SAR (structure-activity relationship) analyses have been performed to determine their biological effects [9] . Derivatives containing quinoline ring has been reported as great antimicrobial [10, 11] , antimalarial [12, 13] and anti-tubercular activities and also exist as structural sub-units of natural substances. Pyrazoles are popular illustrations of aromatic heterocycles incorporating two nitrogen atoms in their five-membered rings [14, 15] . They create an imperative heterocyclic class covering a wide range of synthetic as well as natural products that demonstrate numerous chemical, biological, agrochemical and pharmacological properties [16, 17] . Pyrazole derivatives serve as one of the most effective families of compounds and possess a broad spectrum of biological activities [18] [19] [20] [21] [22] [23] [24] [25] . In recent years, various drugs have been developed from pyrazole derivatives [26] (Fig. 2) .
The current focus of the field suggests that drugs of azole [27, 28] class, pyrazole in particular if coupled with derivatives containing quinoline as core moiety could overcome the problem of drug resistance. On the other hand, drugs containing azole like pyrazoles, derivatives possess a wide range of pharmacological activities like anti-inflammatory [29, 30] , analgesic, anticancer [31, 32] , antiulcer, antimicrobial [33] [34] [35] , antiviral [36, 37] , antimalarial [38] , and anti-arrhythmic [39] . Additionally, quinoline moiety is found to be at the base of a wide variety of naturally existing substances and a key synthon possessing various bioactivities. A library of compounds corresponding to this template with different substituents on both the pharmacophores has been synthesized to explore the possibility of developing new potent antibacterial, antifungal, antitubercular and antimalarial agents. Thus, in the present scheme of reactions (design strategy Fig. 3 ) quinoline skeleton was taken to design new compounds by fusing pyrazole moiety using modified Doebner reaction creating a number of bioactive molecules containing quinoline-pyrazole scaffold.
Results and Discussion
A series of substituted quinoline-pyrazole pharmacophore clubbed compounds were designed and synthesized by employing Doebner reaction Scheme 1. The preparation of substituted pyrazole aldehydes [40] compounds were depicted in Scheme 2. Condensation of substituted acetophenones 1 with substituted phenylhydrazine hydrochlorides 2 in the presence of acetic acid at room temperature provided the corresponding phenylhydrazones 3. Vilsmeier-Haack reaction of 3 in presence of DMF with POCl 3 afforded substituted pyrazole carboxaldehydes 4.
All the titled compounds yielded in the range of 39-78%. Different derivatives of the title compounds are presented in Table 1 . Newly synthesized compounds (7a-n), (8a-g), (9a-g) and (10a-g) were characterized by 1 H NMR, 13 C NMR and Mass spectroscopic methods. 
Pharmacology

In Vitro Antimicrobial Activity
The antibacterial activity of all synthesized compounds (7a-n), (8a-g), (9a-g) and (10a-g) were screened against three Gram-positive bacteria (Bacillus subtilis, Clostridium tetani, Streptococcus pneumonia) and three Gram-negative bacteria (Escherichia coli, Salmonella typhi, Vibrio cholerae) by using ampicillin, norfloxacin and ciprofloxacin as the standard antibacterial drugs. Antifungal activity was screened against two fungal species (Candida albicans and Aspergillus fumigatus) where nystatin and griseofulvin were used as the standard antifungal drugs. The minimal inhibitory concentration (MIC) of all compounds (7a-n), (8a-g), (9a-g) and (10a-g) was determined by the broth microdilution method according to National Committee for Clinical Laboratory Standards (NCCLS) [41] . The inoculum concentration of the test strain was adjusted to 108 CFU (colony-forming units) per cm 3 by comparing the sample turbidity. Mueller-Hinton broth was used as a nutrient medium to grow and dilute the drug suspension for the test. DMSO was used as the diluent to get the desired concentration of compounds to test upon the standard bacterial strains. The obtained results are presented in Table 2 .
In Vitro Antituberculosis Activity
All the synthesized compounds (7a-n), (8a-g), (9a-g) and (10a-g) were evaluated for their in vitro antituberculosis activity against the Mycobacterium tuberculosis H37Rv strain. Screening of all the newly synthesized compounds was conducted at 250 µg/cm 3 by using Lowenstein-Jensen medium as described by Rattan [42] . Rifampicin and Isoniazid were used as standard drugs. The results of antituberculosis screening data are shown in Table 3 . Table 3 in vitro antituberculosis activity (% inhibition) of compounds (7a-n), (8a-g), (9a-g) and (10a-g) against M. tuberculosis H37Rv (at concentrations 250 µg/cm 3 ).
In Vitro Antimalarial Activity
All newly clubbed quinoline-pyrazole derivatives (7a-n), (8a-g), (9a-g) and (10a-g) were evaluated for their Table 4 .
Biological Results
In Vitro Antibacterial and Antifungal Activity
Upon investigation of antimicrobial screening data, it has been observed that the majority of the compounds showed good activity against Gram-positive bacteria. Compounds 7a, 7 l, 8d, 8c, 9b, 9f showed equal potency to ampicillin (MIC = 100 µg/cm 3 ) against B. subtilis and S. pneumoniae. Whereas in inhibiting Gram-negative bacteria, the compounds 7n, 9e, 9 g and 7d showed excellent activity (MIC = 62.5 µg/cm 3 ) against V. cholera and E. coli as compared to ampicillin (MIC = 100 µg/cm 3 ). Compounds 3c against V. cholera showed equal activity as compared to ampicillin (MIC = 100 µg/mL). Aginst C. Albicans, compounds 7d and 7j showed better activity (MIC = 250 and 200 µg/ cm 3 , respectively) and aginst A. Fumigatus compounds 7d and 7j showed equivalent activity (MIC = 500 and 500 µg/ cm 3 , respectively) compared to standard drug Griseofulvin (MIC = 500 µg/cm 3 ). Whereas compound 9d showed similar activity (MIC = 500 µg/cm 3 ) compared to standard drug Griseofulvin (MIC = 500 µg/cm 3 ) against C. Albicans.
Antituberculosis Activity
The cheering results from the antibacterial activity encouraged us to go for preliminary screening of all synthesized compounds for their in vitro antituberculosis activity. Antituberculosis screening of all quinolone-pyrazole derivatives (7a-n), (8a-g), (9a-g) and (10a-g) was conducted at a concentration 250 mg/cm 3 against M. tuberculosis H37Rv strain ( Table 2) . At the commencement of this study in the preliminary screening, compound 9e displayed better activity and showed 92% inhibition. Compound 5g was found to possess excellent activity at both the concentrations i.e. 95%. While compounds 10e and 10f are moderately active against M. tuberculosis H37Rv. All other compounds showed poor inhibition of M. tuberculosis growth. From the above results, it can be concluded that compounds 9e and 9g may become a new class of antitubercular agents in future.
In Vitro Antimalarial Activity
All the compounds (7a-n), (8a-g), (9a-g) and (10a-g) were evaluated for their antimalarial activity against the P. falciparum strain. All experiments were performed in duplicate and the mean value of IC 50 is given in Table 3 . Compounds 9f and 9g were found to have IC 50 in the range of 0.036-0.092 for the P. falciparum strain. These compounds showed principal activity against P. falciparum strain as compared to quinine IC 50 0.268. Whereas compound 9f was found to possess moderate activity i.e. IC 50 0.036 aligned with chloroquine. All other compounds were found to be not as much active as chloroquine and quinine against P. falciparum strain.
Structure-Activity Relationship (SAR)
The substitution on quinoline nucleus (R1) and the FGI (functional group interconversion) increases the biological activity as well as pyrazole substitution (R2 and R3) also Scheme 2 Synthetic route for the title compounds (7a-n), (8a-g), (9a-g) and (10a-g) responsible for enhancing the biological potency. The structure-activity relationship study is shown in Fig. 4 .
Conclusion
A library of quinoline-pyrazole clubbed derivatives (7a-n), (8a-g), (9a-g) and (10a-g) were developed from substituted aniline, substituted-1H-pyrazole-4-carbaldehydes and pyruvic acid. All the synthesized compounds were characterized by analytical and spectral data ( 1 H NMR, 13 C NMR and Mass Spectroscopy) and are in full compliance with the suggested structure. Pyrazole-quinoline core structure derivatives enhanced their antibacterial, antimalarial and antimycobacterial activity, as is conspicuous from the biological evaluation results. Most of the compounds were found to be potent against tested microorganisms with moderate to good activity. For the specific bacterial strains, a majority of the compounds acquired the adjacent antibacterial potential to ampicillin, Norfloxacin, Ciprofloxacin, Nystatin and Griseofulvin.
Experimental
Materials
All the reactants were reagent grade, and purchased from Sigma Aldrich, and used without further purification unless otherwise stated. DCM (dichloromethane) and THF (tetrahydrofuran) were distilled from Calcium hydride (desiccant) and sodium benzophenone ketyl, respectively. All solvents were used without further drying or purification and were of ACS grade purchased from local suppliers. TLC plates (Silica Gel) were purchased from Sigma-Aldrich.
Instrumentation
Melting points were determined in open capillary tubes on a Stuart SMP 10 melting point apparatus and are uncorrected. Elemental analysis data were obtained with Perkin Elmer C, H, N analyser model 2400. Nuclear Magnetic Spectroscopy (NMR) spectra were produced using the Varian 400 MHz spectrometer. The instrument was maintained at 25 °C operating at 400 MHz for 1 H NMR, and 100 MHz for 13 C NMR. The deuterated solvent (DMSO-d 6 ) used for each respective spectrum is referenced to the appropriate literature peak shift. Mass spectra were recorded on a Shimadzu LC/MS 2010 spectrometer. The Microwave-assisted reactions were performed in a QLABPro closed vessel microwave digestion system.
General Procedure for the Synthesis of (7a-n)
Into a 2 dm 3 three-neck round-bottom flask equipped with a stirring bar magnet, a reflux condenser, and a dropping funnel and set above a heating mantle, (0.0535 mol) substituted pyrazole aldehydes, (0.0535 mol) Substituted aniline, and 520 cm 3 absolute ethanol was introduced. The mixture was stirred and heated gently until pyrazole aldehydes and aniline had dissolved to form a brown solution. The mixture was then allowed to reflux for ~ 60 min. In the meantime, a mixture of (0.0535 mol) pyruvic acid and 208.3 cm 3 absolute ethanol were prepared and placed in an addition (7a-n), (8a-g), (9a-g) and (10a-g) a Isolated yields
funnel. After the reaction mixture had refluxed for ~ 60 min, the pyruvic acid solution was allowed to drop at a rate of two drops per second into the mixture. Within ~ 30 min, the addition of the pyruvic acid solution was complete, and the reaction mixture was allowed to reflux for approximately 5 days. Good yield of a white, powdery compound was collected (suction filtered) and recrystallized from ethanol. 4.4 General Procedure for the Synthesis of 8a-g 5 .0 g pyrazole-quinolinecarboxylic acid, 62.63 cm 3 dried and redistilled thionyl chloride was added to a 250 cm 3 round-bottom flask equipped with a condenser tube, a drying tube and a magnetic stir bar, then heated with stirring for 6 h. The mixture was cooled to room temperature, and distilled under reduced pressure to remove excess thionyl chloride, then dried in vacuum. The residues were washed with petroleum ether and then dissolved in 10 cm 3 toluene and concentrated under reduced pressure to afford the title compound.
General Procedure for the Synthesis of 9a-g
To the 250 cm 3 , three neck flask equipped with the thermometer, the addition funnel and the stirrer, 70 cm 3 of tetrahydrofuran or ether, 5.3 g of N, N-dimethylaminoethylamine and 35 cm 3 of triethylamine or DIPEA (diisopropylethylamine) was taken up. The solution was cooled to 0 °C and the solution of 9.4 g of compounds (8a-g) in 65 cm 3 tetrahydrofuran or ether was added dropwise for 40 min under cooling and stirring so as the temperature did not exceed 0-15 °C. The mixture was then stirred for 24 h at room temperature. 150 cm 3 of petroleum ether or hexane was added to the mixture. The semi-solid product was filtered off and macerated with 20 cm 3 of ice-cooled saturated aqueous sodium chloride solution. The solid product was separated, washed once with 15 cm 3 saturated aqueous sodium chloride solution, two times with ice water and purified with crystallization from the water: ethanol (2:1). The crude product was purified by column chromatography using ethyl acetate/NMM/methanol (98/1/1). Afforded white solid. and extracted with EtOAc (3 × 70 cm 3 ). The organic fraction was dried over Na 2 SO4, filtered by suction and concentrated in vacuum. The resulting crude material was purified by flash silica gel column chromatography (EtOAc/pet-ether 1:3 → 1:0), The product was further purified via preparative reversed phase HPLC using a 10 μm Gemini C18 column (Phenomenex) under isocratic conditions with acetonitrile/ 
General Procedure for the Synthesis of 10a-g
